- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05078749
The Effects of Telerehabilitation Based Exercise Program in Patients With Systemic Sclerosis
Systemic Sclerosis (Ssc) is a rare, systemic autoimmune disease characterized by skin fibrosis and vasculopathy. In addition to the skin, it is a heterogeneous disease that affects multiple organs, including the musculoskeletal, cardiac, pulmonary, and gastrointestinal systems. Patients may experience many symptoms such as pain, fatigue, dyspnea, impaired hand function, dry mouth, and difficulty sleeping. As a result of these symptoms, these patients may experience a decrease in activities of daily living, physical activity level and quality of life, while psychological problems such as anxiety and depression may increase. In addition to medical treatment, rehabilitation programs for the patient are an important part of treatment to eliminate or reduce these symptoms and their consequences.
Many problems such as time and resource constraints, transportation problems prevent access and compliance with the rehabilitation program. Also; For the coronavirus disease 2019 (COVID-19) epidemic that emerged in Wuhan, China in 2019, many countries have implemented many practices such as social distance, mandatory quarantine and transportation restrictions in order to better control the spread of the virus. Many people with SSc are at risk of serious complications from COVID-19 if infected due to lung involvement (>40% have interstitial lung disease) and widespread use of immunosuppressant drugs. Most countries have recommended that people with medical conditions such as SSc undergo strict isolation during the COVID-19 pandemic. As a result, patients' access to the rehabilitation program became more difficult in this process. In addition, social isolation due to the COVID-19 outbreak may increase physical inactivity and cause complications that may develop accordingly.
When the literature was examined, no studies were found showing the effect of telerehabilitation program on anxiety depression, physical activity, sleep, fatigue and quality of life in patients with SSc.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ankara
-
Çankaya, Ankara, Turkey
- Recruiting
- Gazi University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients between the ages of 18-65
- Being literate
- Patients who received standard medical treatment and whose general condition has been stable for the last 6 months
- Having minimum smartphone or computer usage knowledge or having an acquaintance who knows this information and can help with this
- Having a computer and active internet connection at home
- Disease duration between 1 and 10 years
- Agree to participate in the study
Exclusion Criteria:
- Patients who cannot cooperate with the assessment
- Those who have orthopedic problems or neurological diseases that prevent them from doing the exercises
- Those who received treatment in a physiotherapy and rehabilitation program before
- Patients with another inflammatory disease
- Female patients who are pregnant
- Patients who have had COVID-19
- Those with a diagnosis of pulmonary arterial hypertension (PAH)
- Exercise is contraindicated for those with heart disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Exercise training group
Continuous progressive exercise training will be applied to the treatment group.
The exercises will be performed every day, twice a day, for an average of 10 minutes/session, for eight weeks.
Exercise training will be updated regularly at two-week intervals.
A different and progressive new exercise will be sent to the patients as a Youtube link.
The patients will be interviewed by video every week.
|
A regular advanced exercise program will be given and followed.
|
Sham Comparator: Control training group
The control group will be followed up as a home program by explaining the exercises and giving a brochure.
They will be asked to do the exercises regularly for 7 days/week, 2 sessions/day, for eight weeks.
Patients in the control group will be followed up by phone once a week.
|
Basic exercises will be given at the beginning and will do the same exercises
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Numerical Evaluation Scale-Pain
Time Frame: First day
|
The Numeric Rating Scale (NRS) was used to determine the pain level of the patients at rest, activity and at night.
Patients are asked to mark the numbers between 0 and 10 at the time of assessment, in terms of rest, activity and night pain.
10 score describe severe pain while 0 score is no pain
|
First day
|
Modified Medical Research Council Dyspnea Scale
Time Frame: First day
|
Assessment of dyspnea was assessed with the Modified Medical Research Council (MMRC) dyspnea scale.
The MMRC is a category scale consisting of 5 statements about dyspnea, scored between 0-4.
As the score obtained by the patient increases, the complaint of dyspnea increases.
|
First day
|
Multidimensional Assessment of Fatigue Scale
Time Frame: First day
|
Fatigue assessment will be evaluated with the Turkish Version of the Multidimensional Fatigue Scale (MAF-T).
The MAF-T is a 4-dimensional questionnaire that assesses the degree and severity of fatigue, the amount, duration, and type of distress it causes.
According to their answers, the patients score at least 1 (no fatigue) and 50 (severe fatigue) points from the test.
|
First day
|
International Physical Activity Questionnaire-short form
Time Frame: First day
|
Physical activity level was evaluated with Turkish valid and reliable International Physical Activity (IPAQ) questionnaire.
The questionnaire consisting of 7 questions gives information about the time spent in walking, moderate-to-vigorous and vigorous activities.
The time spent sitting is considered as a separate question.
A score is obtained in total score metabolic equivalent (MET)-minutes.
According to the result, physical activity level is classified as 'inactive', 'minimally active' and 'very active'.
|
First day
|
Pittsburgh sleep quality index
Time Frame: First day
|
Sleep will be assessed by the Pittsburgh sleep quality index (PUKI).
The questionnaire consists of a total of 24 questions; The first 19 questions are answered by the person, and the last 5 questions are answered by the person's family or roommate.
The total score of the questionnaire varies between 0-21.
The higher the PUKI score, the worse the sleep quality is.
A total PUKI score of < 5 indicates 'good' sleep quality, and a total PUKI score of ≥ 5 indicates 'poor' sleep quality.
|
First day
|
Hospital Anxiety and Depression Scale
Time Frame: First day
|
A valid and reliable Turkish Hospital Anxiety and Depression Scale (HADS) was used to determine the anxiety and depression levels of the patients.
In the questionnaire consisting of a total of 14 questions, odd-numbered questions assess anxiety and even-numbered questions assess depression.
It has two subgroups, anxiety (HADS-A) and depression (HADS-D).
The lowest score that patients can get from both subgroups is 0, and the highest score is 21.
|
First day
|
Nottingham Health Profile
Time Frame: First day
|
Quality of life will be assessed with the Turkish version of the Notthingham Health Profile (NSP) scale.
NSP evaluates the physical, social and emotional health problems perceived by the patient at that moment in 2 parts.
Each subgroup is scored between 0-100 in itself.
The total score of the NSP questionnaire is between 0-600.
A high score indicates poor quality of life.
|
First day
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 208
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Sclerosis
-
Horizon Pharma Ireland, Ltd., Dublin IrelandEnrolling by invitationDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicKorea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
-
Horizon Therapeutics Ireland DACRecruitingDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicNetherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
-
Michael M. PhamTerminatedSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
University of ManchesterCompletedEarly Diffuse Cutaneous Systemic Sclerosis
-
Fred Hutchinson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSystemic Scleroderma | Severe Systemic SclerosisUnited States
-
Kadmon, a Sanofi CompanyTerminatedDiffuse Cutaneous Systemic Sclerosis | System; SclerosisUnited States
-
Boston UniversityCompleted
-
Federal University of São PauloUnknown
-
Lawson Health Research InstituteMallinckrodtNot yet recruitingDiffuse Cutaneous Systemic SclerosisCanada
Clinical Trials on Exercise training group
-
Riphah International UniversityCompletedHypertension | ObesePakistan
-
Eastern Mediterranean UniversityCompleted
-
Istanbul University - Cerrahpasa (IUC)CompletedRotator Cuff Tear or Rupture, Not Specified as Traumatic | Pain, ShoulderTurkey
-
Riphah International UniversityCompletedSpinal Cord InjuriesPakistan
-
Gazi UniversityCompleted
-
Gazi UniversityNot yet recruiting
-
Gazi UniversityCompletedHematopoietic Stem Cell TransplantationTurkey
-
Federal University of Juiz de ForaCompleted
-
State University of MaringáCompleted
-
Medipol UniversityRecruitingChronic Low Back PainTurkey